{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T01:01:06Z","timestamp":1776128466701,"version":"3.50.1"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100009964","name":"Tangshan Science and Technology Bureau","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009964","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009076","name":"University of Science and Technology of China","doi-asserted-by":"publisher","award":["2025S30"],"award-info":[{"award-number":["2025S30"]}],"id":[{"id":"10.13039\/501100009076","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry Letters"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.bmcl.2026.130618","type":"journal-article","created":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T16:23:37Z","timestamp":1773246217000},"page":"130618","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Design, synthesis, and anti-tumor evaluation of indolin-2-one derivatives based on 3D-QSAR"],"prefix":"10.1016","volume":"136","author":[{"given":"Xingdan","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liying","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ziqi","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinyue","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Bai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qidi","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.bmcl.2026.130618_bb0005","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1146\/annurev.biochem.72.121801.161629","article-title":"Trk receptors: roles in neuronal signal transduction","volume":"72","author":"Huang","year":"2003","journal-title":"Annu Rev Biochem"},{"issue":"11","key":"10.1016\/j.bmcl.2026.130618_bb0010","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1002\/neu.480251107","article-title":"The Trk family of neurotrophin receptors","volume":"25","author":"Barbacid","year":"1994","journal-title":"J Neurobiol"},{"issue":"3","key":"10.1016\/j.bmcl.2026.130618_bb0015","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/S0959-4388(00)00208-7","article-title":"Trk receptors: mediators of neurotrophin action","volume":"11","author":"Patapoutian","year":"2001","journal-title":"Curr Opin Neurobiol"},{"issue":"4","key":"10.1016\/j.bmcl.2026.130618_bb0020","doi-asserted-by":"crossref","DOI":"10.3390\/cancers10040105","article-title":"Inhibiting TRK proteins in clinical cancer therapy","volume":"10","author":"Lange","year":"2018","journal-title":"Cancers"},{"issue":"6056","key":"10.1016\/j.bmcl.2026.130618_bb0025","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1038\/319743a0","article-title":"A human oncogene formed by the fusion of truncated tropomyosin and protein tyrosine kinase sequences","volume":"319","author":"Martin-Zanca","year":"1986","journal-title":"Nature"},{"key":"10.1016\/j.bmcl.2026.130618_bb0030","doi-asserted-by":"crossref","first-page":"viii23","DOI":"10.1093\/annonc\/mdz282","article-title":"TRK inhibitors in TRK fusion-positive cancers","volume":"30","author":"Drilon","year":"2019","journal-title":"Ann Oncol"},{"issue":"7","key":"10.1016\/j.bmcl.2026.130618_bb0035","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14071793","article-title":"Indirect treatment comparison of larotrectinib versus entrectinib in treating patients with TRK gene fusion cancers","volume":"14","author":"Garcia-Foncillas","year":"2022","journal-title":"Cancers"},{"issue":"18","key":"10.1016\/j.bmcl.2026.130618_bb0040","doi-asserted-by":"crossref","first-page":"4974","DOI":"10.1158\/1078-0432.CCR-21-0465","article-title":"Tropomyosin receptor kinase inhibitors for the treatment of TRK fusion cancer","volume":"27","author":"Laetsch","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.bmcl.2026.130618_bb0045","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.2147\/TCRM.S147381","article-title":"Entrectinib: an orally available, selective tyrosine kinase inhibitor for the treatment of NTRK, ROS1, and ALK fusion-positive solid tumors","author":"Liu","year":"2018","journal-title":"Ther Clin Risk Manag"},{"issue":"4","key":"10.1016\/j.bmcl.2026.130618_bb0050","first-page":"418","article-title":"Larotrectinib and entrectinib: TRK inhibitors for the treatment of pediatric and adult patients with NTRK gene fusion","volume":"11","author":"Dunn","year":"2020","journal-title":"J Adv Pract Oncol"},{"issue":"5","key":"10.1016\/j.bmcl.2026.130618_bb0055","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1080\/14737140.2020.1747439","article-title":"Entrectinib for the treatment of metastatic NSCLC: safety and efficacy","volume":"20","author":"Sartore-Bianchi","year":"2020","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1016\/j.bmcl.2026.130618_bb0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.117231","article-title":"Design, synthesis and biological evaluation of novel 1H-indole-3-carbonitrile derivatives as potent TRK inhibitors","volume":"285","author":"Xu","year":"2025","journal-title":"Eur J Med Chem"},{"issue":"14","key":"10.1016\/j.bmcl.2026.130618_bb0065","doi-asserted-by":"crossref","first-page":"10286","DOI":"10.1021\/acs.jmedchem.1c00712","article-title":"Discovery of the next-generation pan-TRK kinase inhibitors for the treatment of cancer","volume":"64","author":"Liu","year":"2021","journal-title":"J Med Chem"},{"issue":"10","key":"10.1016\/j.bmcl.2026.130618_bb0070","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.2174\/0929867329666220801145639","article-title":"Research progress on small molecules inhibitors targeting TRK kinases","volume":"30","author":"Liu","year":"2023","journal-title":"Curr Med Chem"},{"issue":"8","key":"10.1016\/j.bmcl.2026.130618_bb0075","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0270571","article-title":"Real-world survival outcomes in patients with locally advanced or metastatic NTRK fusion-positive solid tumors receiving standard-of-care therapies other than targeted TRK inhibitors","volume":"17","author":"Hibar","year":"2022","journal-title":"PLoS One"},{"issue":"16","key":"10.1016\/j.bmcl.2026.130618_bb0080","doi-asserted-by":"crossref","first-page":"2390","DOI":"10.1021\/jm00068a017","volume":"36","author":"Waller","year":"1993","journal-title":"J Med Chem"},{"issue":"14","key":"10.1016\/j.bmcl.2026.130618_bb0085","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.2174\/1389557520666200204123156","article-title":"The QSAR paradigm in fragment-based drug discovery: from the virtual generation of target inhibitors to multi-scale modeling","volume":"20","author":"Kleandrova","year":"2020","journal-title":"Mini Rev Med Chem"},{"issue":"2","key":"10.1016\/j.bmcl.2026.130618_bb0090","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1517\/17460441.2016.1118046","article-title":"QSAR studies in the discovery of novel type-II diabetic therapies","volume":"11","author":"Abuhammad","year":"2016","journal-title":"Expert Opin Drug Discov"},{"issue":"11","key":"10.1016\/j.bmcl.2026.130618_bb0095","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.2174\/0929867328666210831142311","article-title":"The development of 3-substituted indolin-2-one derivatives as kinase inhibitors for cancer therapy","volume":"29","author":"Xu","year":"2022","journal-title":"Curr Med Chem"},{"issue":"15","key":"10.1016\/j.bmcl.2026.130618_bb0100","doi-asserted-by":"crossref","first-page":"6002","DOI":"10.1021\/acs.jmedchem.5b00571","article-title":"Design, synthesis, and characterization of 3-(benzylidene) indolin-2-one derivatives as ligands for \u03b1-synuclein fibrils","volume":"58","author":"Chu","year":"2015","journal-title":"J Med Chem"},{"issue":"2","key":"10.1016\/j.bmcl.2026.130618_bb0105","doi-asserted-by":"crossref","DOI":"10.1002\/slct.202303622","article-title":"Design of new Second-Generation TRK inhibitors targeting tropomyosin receptor kinases by using molecular docking, molecular dynamics simulations and ADMET properties","volume":"9","author":"Zhao","year":"2024","journal-title":"ChemistrySelect"},{"issue":"12","key":"10.1016\/j.bmcl.2026.130618_bb0110","first-page":"161","article-title":"Analysis and optimization of nitrification reaction conditions from the perspective of mechanism and dynamics","volume":"36","author":"Huo","year":"2021","journal-title":"Coll Chem"},{"issue":"37","key":"10.1016\/j.bmcl.2026.130618_bb0115","article-title":"Cover feature: asymmetric reductive amination in organocatalysis and biocatalysis","volume":"26","author":"Li","year":"2023","journal-title":"Eur J Org Chem"},{"issue":"47","key":"10.1016\/j.bmcl.2026.130618_bb0120","doi-asserted-by":"crossref","first-page":"7368","DOI":"10.1002\/ejoc.202001408","article-title":"CO\u2082 - controlled reductive amination reactions with NaBH\u2084","volume":"2020","author":"Petresen","year":"2020","journal-title":"Eur J Org Chem"},{"issue":"5","key":"10.1016\/j.bmcl.2026.130618_bb0125","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s00706-020-02586-6","article-title":"Applications of Knoevenagel condensation reaction in the total synthesis of natural products","volume":"151","author":"Heravi","year":"2020","journal-title":"Mon Chem - Chem Mon"},{"issue":"1","key":"10.1016\/j.bmcl.2026.130618_bb0130","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1002\/cber.18960290133","article-title":"The preparation of benzylidene acetoacetic esters","volume":"29","author":"Knoevenagel","year":"1896","journal-title":"Chem Ber"},{"issue":"1","key":"10.1016\/j.bmcl.2026.130618_bb0135","doi-asserted-by":"crossref","DOI":"10.1186\/s13046-019-1104-4","article-title":"A selective c-Met and Trks inhibitor Indo5 suppresses hepatocellular carcinoma growth","volume":"38","author":"Luo","year":"2019","journal-title":"J Exp Clin Cancer Res"},{"issue":"11","key":"10.1016\/j.bmcl.2026.130618_bb0140","doi-asserted-by":"crossref","DOI":"10.1038\/s41419-023-06246-5","article-title":"A novel c-met\/TRK inhibitor 1D228 efficiently inhibits tumor growth by targeting angiogenesis and tumor cell proliferation","volume":"14","author":"An","year":"2023","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.bmcl.2026.130618_bb0145","doi-asserted-by":"crossref","unstructured":"Antila H, Autio H, Turunen L, Harju K, Tammela P, Wennerberg K, Yli-Kauhaluoma J, J. HuttunnH, Castr\u00e9n E, Rantam\u00e4ki T. Utilization of in situ ELISA method for examining Trk receptor phosphorylation in cultured cells. J Neurosci Methods, 2014, 222: 142\u2013146.","DOI":"10.1016\/j.jneumeth.2013.11.001"}],"container-title":["Bioorganic & Medicinal Chemistry Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X26000855?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X26000855?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T00:22:45Z","timestamp":1776126165000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960894X26000855"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":29,"alternative-id":["S0960894X26000855"],"URL":"https:\/\/doi.org\/10.1016\/j.bmcl.2026.130618","relation":{},"ISSN":["0960-894X"],"issn-type":[{"value":"0960-894X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Design, synthesis, and anti-tumor evaluation of indolin-2-one derivatives based on 3D-QSAR","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmcl.2026.130618","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"130618"}}